While the COVID-19 pandemic and ensuing shutdowns around the globe have seemingly brought much of society to a grinding halt, that’s not necessarily the case with patents—especially those related to COVID-19.
As we’ve explored previously, (COVID-19 & IP Laws: Should Drug Patent Holders Be Concerned? and How COVID-19 is Impacting Intellectual Property Laws), governments and other entities are streamlining or even reducing patent requirements in an effort to get potentially lifesaving medications and procedures to market.
